Cantor Fitzgerald restated their overweight rating on shares of Capricor Therapeutics (NASDAQ:CAPR – Free Report) in a research report report published on Friday, Benzinga reports. Cantor Fitzgerald currently has a $8.00 price objective on the biotechnology company’s stock.
A number of other research firms have also recently weighed in on CAPR. HC Wainwright reissued a buy rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research note on Tuesday. Maxim Group reiterated a buy rating and issued a $12.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday. Finally, Oppenheimer raised their target price on Capricor Therapeutics from $14.00 to $15.00 and gave the stock an outperform rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and a consensus target price of $20.00.
Read Our Latest Stock Analysis on CAPR
Capricor Therapeutics Trading Up 1.2 %
Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) last issued its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.03). The firm had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative return on equity of 220.27% and a negative net margin of 102.93%. Sell-side analysts predict that Capricor Therapeutics will post -1.24 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of CAPR. Marshall Wace LLP bought a new position in Capricor Therapeutics in the 2nd quarter valued at $426,000. Renaissance Technologies LLC lifted its position in Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock worth $656,000 after buying an additional 84,350 shares in the last quarter. Main Street Financial Solutions LLC grew its holdings in Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares during the last quarter. Rhumbline Advisers bought a new stake in Capricor Therapeutics during the 2nd quarter worth about $147,000. Finally, Bank of New York Mellon Corp increased its position in Capricor Therapeutics by 12.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after acquiring an additional 9,040 shares in the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Featured Articles
- Five stocks we like better than Capricor Therapeutics
- How to Calculate Options Profits
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- The How And Why of Investing in Oil Stocks
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.